|
Jul 24
|
AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option
|
|
Jul 24
|
AlzeCure's Rights Issue Oversubscribed According to Preliminary Results
|
|
Jul 23
|
3 European Penny Stocks With Market Caps Under €30M
|
|
Jul 21
|
AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference
|
|
Jul 16
|
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue
|
|
Jul 2
|
The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares
|
|
Jun 24
|
European Penny Stocks To Watch In June 2025
|
|
Apr 9
|
Notice to Annual General Meeting in AlzeCure Pharma AB
|
|
Feb 24
|
New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment
|
|
Feb 17
|
AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease
|
|
Oct 17
|
AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day
|
|
Oct 10
|
AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain
|
|
Jun 13
|
New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain
|
|
Apr 10
|
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board
|
|
Feb 12
|
AlzeCure Pharma Broadcasts Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators
|
|
Dec 7
|
AlzeCure Presents at Redeye Investor Forum in Göteborg on December 14
|
|
Nov 9
|
AlzeCure Publishes its Interim Report for January - September 2023
|
|
Oct 19
|
AlzeCure's Alzheimer Project NeuroRestore ACD856 is also Granted a Patent in Japan
|
|
Oct 17
|
AlzeCure Publishes New Article on the GSM Mechanism Behind Alzstatin Against Alzheimer's Disease
|
|
Sep 20
|
AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference
|